These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31339212)

  • 1. Real-world versus trial patients with transthyretin amyloid cardiomyopathy.
    Canepa M; Tini G; Musumeci B; Cappelli F; Milandri A; Mussinelli R; Autore C; Perfetto F; Rapezzi C; Perlini S
    Eur J Heart Fail; 2019 Nov; 21(11):1479-1481. PubMed ID: 31339212
    [No Abstract]   [Full Text] [Related]  

  • 2. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
    Maurer MS; Elliott P; Merlini G; Shah SJ; Cruz MW; Flynn A; Gundapaneni B; Hahn C; Riley S; Schwartz J; Sultan MB; Rapezzi C;
    Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal evolution of ventricular function and cardiac magnetic resonance imaging tissue characteristics in tafamidis-treated transthyretin amyloid cardiomyopathy.
    Dobner S; Bernhard B; Wieser M; Wahl A; Stark AW; Köchli V; Spano G; Boscolo Berto M; Johner C; Elchinova E; Tanner G; Safarkhanlo Y; Stortecky S; Schütze J; Hunziker Munsch L; Gräni C
    Amyloid; 2024 Jun; 31(2):145-147. PubMed ID: 38069637
    [No Abstract]   [Full Text] [Related]  

  • 4. A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.
    Endo J; Sano M; Izumiya Y; Tsujita K; Nakamura K; Tahara N; Kuwahara K; Inomata T; Ueda M; Sekijima Y; Ando Y; Tsutsui H; Isobe M; Fukuda K
    Circ J; 2019 Dec; 84(1):15-17. PubMed ID: 31735731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tafamidis: A Novel Treatment for Transthyretin Amyloid Cardiomyopathy.
    Nawarskas JJ; Shephard EA
    Cardiol Rev; 2020; 28(3):156-160. PubMed ID: 32101907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
    Maurer MS; Schwartz JH; Gundapaneni B; Elliott PM; Merlini G; Waddington-Cruz M; Kristen AV; Grogan M; Witteles R; Damy T; Drachman BM; Shah SJ; Hanna M; Judge DP; Barsdorf AI; Huber P; Patterson TA; Riley S; Schumacher J; Stewart M; Sultan MB; Rapezzi C;
    N Engl J Med; 2018 Sep; 379(11):1007-1016. PubMed ID: 30145929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transthyretin Stabilizer Is Associated With Expanding Apical Sparing Area and Improving Global Cardiac Function in a Patient With Wild-Type Cardiac Amyloidosis.
    Kato TS; Ikeda N; Maurer MS; Ando Y; Tanno K
    Circ J; 2019 Feb; 83(3):690. PubMed ID: 30185690
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
    Hanna M; Damy T; Grogan M; Stewart M; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
    Am J Cardiol; 2021 Feb; 141():98-105. PubMed ID: 33220323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
    Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
    J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letter by Rozenbaum et al Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy".
    Rozenbaum MH; Kemner J; Parasuraman B
    Circulation; 2020 Oct; 142(15):e210-e211. PubMed ID: 33044864
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy.
    Kazi DS; Bellows BK; Baron SJ; Shen C; Cohen DJ; Spertus JA; Yeh RW; Arnold SV; Sperry BW; Maurer MS; Shah SJ
    Circulation; 2020 Apr; 141(15):1214-1224. PubMed ID: 32078382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter by Baldovino et al Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy".
    Baldovino S; Costanzo P; Roccatello D
    Circ Heart Fail; 2022 Jul; 15(7):e009617. PubMed ID: 35748294
    [No Abstract]   [Full Text] [Related]  

  • 14. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
    Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
    Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
    [No Abstract]   [Full Text] [Related]  

  • 15. Response by Elliott et al to Letter Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy".
    Elliott P; Gundapaneni B; Sultan MB
    Circ Heart Fail; 2022 Jul; 15(7):e009637. PubMed ID: 35748240
    [No Abstract]   [Full Text] [Related]  

  • 16. Response by Kazi et al to Letter Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy".
    Kazi DS; Bellows BK; Spertus JA; Baron SJ; Shen C; Cohen DJ; Yeh RW; Arnold SV; Sperry BW; Maurer MS; Shah SJ
    Circulation; 2020 Oct; 142(15):e212-e213. PubMed ID: 33044859
    [No Abstract]   [Full Text] [Related]  

  • 17. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
    Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?
    Falk RH
    Eur Heart J; 2019 Mar; 40(12):1009-1012. PubMed ID: 30668704
    [No Abstract]   [Full Text] [Related]  

  • 19. What is this image? 2022 image 1 result: radiologic improvement of transthyretin cardiac amyloidosis after treatment with tafamidis.
    Mekritthikrai R; Gomez-Valencia J; Malhotra S
    J Nucl Cardiol; 2022 Aug; 29(4):1500-1502. PubMed ID: 35715715
    [No Abstract]   [Full Text] [Related]  

  • 20. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
    Merkies IS
    Neurology; 2013 Apr; 80(15):1444-5. PubMed ID: 23569001
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.